Skip to main navigation Skip to search Skip to main content

Thrombocytopenic Purpura in Childhood

  • Maria C. Bouw
  • , Natasja Dors
  • , Heleen van Ommen
  • , Nicole L. Ramakers-Van Woerden*
  • *Corresponding author for this work
  • Emma Children’s Hospital
  • External organisation

Research output: Contribution to journalReview articleAcademicpeer-review

27 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare disease, especially in childhood, and has a high mortality rate in the absence of appropriate treatment. It is characterised by microangiopathic haemolytic anaemia and consumptive thrombocytopenia. TTP may be difficult to distinguish from haemolytic uraemic syndrome (HUS) because of similar clinical manifestations and laboratory findings. In the past, TTP and HUS have often been considered to represent variable expressions of a single entity. Our increased understanding of the pathogenesis of TTP has in turn resulted in significant improvements in its treatment and outcomes. Several immunomodulating agents are currently being used with variable outcomes. Pediatr Blood Cancer 2009;53:537–542. © 2009 Wiley-Liss, Inc.
Original languageEnglish
Pages (from-to)537-542
JournalPediatric Blood and Cancer
Volume53
Issue number4
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Bibliographical note

© 2009 Wiley-Liss, Inc

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Thrombocytopenic Purpura in Childhood'. Together they form a unique fingerprint.

Cite this